Skip to main content
Fig. 5 | Clinical Epigenetics

Fig. 5

From: Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells

Fig. 5

Treatment with MAKV-8 leads to cell cycle arrest and apoptotic cell death. K-562 cells were treated with MAKV-8 at the indicated time points and concentrations, followed by analyses of (a) cell cycle distribution using a range of subtoxic cytostatic MAKV-8 concentrations to focus only on aspects of cell cycle modulation, (b) nuclear morphology, and (c) caspase and PARP-1 activation. (b) Representative pictures of cells stained with Hoechst in blue and propidium iodide (PI) in red (upper left panel) and corresponding quantifications (lower right panel) from three independent experiments are provided. Where indicated, cells were pre-incubated for 1h with the pan-caspase inhibitor z-VAD-FMK. Cisplatin was used as a positive control for caspase and PARP-1 cleavage. Blots used β-actin as the loading control and are representative of three independent experiments. SAHA was used as a reference HDACi

Back to article page